Olr655 inhibitors represent a class of chemical compounds that function by specifically targeting and inhibiting the activity of the Olr655 receptor, which is a part of the olfactory receptor family. These receptors are G-protein-coupled receptors (GPCRs) located in the sensory neurons of the olfactory epithelium. The Olr655 receptor is involved in the detection and signal transduction of specific odorant molecules, which play a crucial role in the perception of smell. Inhibition of Olr655 activity can result in altered olfactory signaling, leading to changes in odor perception. This class of inhibitors typically interacts with the receptor's binding site, preventing the natural odorant molecules from binding and activating the receptor, thus blocking the subsequent signal transduction pathways.
Chemically, Olr655 inhibitors can be structurally diverse, including small organic molecules, peptides, or even larger macromolecular complexes. These inhibitors are designed to exhibit high specificity and affinity for the Olr655 receptor to ensure effective inhibition. Structural studies often employ techniques like X-ray crystallography or NMR spectroscopy to elucidate the binding interactions between the inhibitors and the Olr655 receptor. This structural information is critical for rational design and optimization of inhibitors with improved potency and selectivity. Additionally, computational methods such as molecular docking and molecular dynamics simulations are frequently utilized to predict and analyze the binding modes of these inhibitors. Overall, the study and development of Olr655 inhibitors provide valuable insights into the molecular mechanisms of olfactory signal transduction and the functional role of specific olfactory receptors in the broader context of sensory biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Zanubrutinib | 1691249-45-2 | sc-507434 | 5 mg | $360.00 | ||
Bruton's tyrosine kinase inhibitor, potentially affecting proteins in B-cell receptor signaling pathways. | ||||||
IPI 145 | 1201438-56-3 | sc-488318 | 5 mg | $317.00 | ||
PI3K inhibitor, potentially disrupting proteins in the AKT/mTOR signaling pathway. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor, potentially influencing proteins in cytokine signaling pathways. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
HDAC inhibitor, potentially impacting gene expression and chromatin remodeling proteins. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Another HDAC inhibitor, potentially affecting gene expression and proteins involved in chromatin structure. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
MEK inhibitor, potentially disrupting proteins in the MAPK/ERK pathway. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Bruton's tyrosine kinase inhibitor, potentially influencing proteins in B-cell receptor signaling pathways. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
MEK inhibitor, potentially affecting proteins in the MAPK/ERK signaling pathway. | ||||||
TGR-1202 | 1532533-67-7 | sc-507436 | 25 mg | $286.00 | ||
PI3K delta and CK1 epsilon inhibitor, potentially impacting proteins in cell signaling and survival pathways. | ||||||